Adoptive cell therapy using tumor-specific T cells is a promising strategy for treating patients with malignancy. However, accumulating evidences have demonstrated that optimal function of tumor-reactive T cells is often attenuated by negative regulatory signal(s) delivered through receptors, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-1), and their cognate ligands. Although systemic blocking of these molecules needs careful attention on the risk of uncontrolled immune activation, selective inhibition of negative signals in tumor-specific T cells by their genetic modification is an attractive approach to overcome immunological suppression in cancer patients. Here, we demonstrate the improved effector functions of tumor-specific CD4 þ and CD8 þ human T cells by small interfering RNA (siRNA) -mediated silencing of PD-1 ligands, PD-L1 or PD-L2. Tumor antigen MAGE-A4-specific human T-cell clones upregulated the expression of PD-1 ligands upon activation. siRNA-mediated knockdown of PD-L1 or -L2 enhanced the interferon-g production and antigen-specific cytotoxicity of these cells. Peripheral blood mononuclear cells transduced with a retroviral vector encoding MAGE-A4-specific T-cell receptor a/b chains also increased their effector functions by this modification. These results suggest that siRNA-mediated knockdown of PD-1 ligands is an attractive strategy to inhibit a negative regulatory mechanism of tumor-specific T cells resulting in enhanced efficacy of adoptive T-cell therapy of cancer using genetically modified autologous lymphocytes.
INTRODUCTION
Adoptive T-cell therapy, involving the transfer of antigen-specific T cells that are selected and expanded ex vivo, represents a promising therapeutic approach for the treatment of cancer patients. 1 However, efficacies of adoptive cell therapy (ACT) are thought to be often hampered by various immunosuppressive mechanisms developed in tumor-bearing hosts. 2, 3 Genetic engineering can offer a means to endow T cells with enhanced functions and resistance to tumor-mediated immunosuppression. These include genes encoding homeostatic or pro-inflammatory cytokines, chemokine receptors, anti-apoptotic molecules, costimulatory molecules and silencing sequence of coinhibitory molecules. 1, 3, 4 Over the years, growing number of B7/CD28 family of costimulatory and coinhibitory molecules have been emerged as important regulators of T-cell activation. The programmed death 1 (PD-1) receptor and its two ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), are members of this family. PD-1/PD-1 ligand pathway has important roles in the negative regulation of immune responses and the maintenance of peripheral tolerance. 5, 6 Several recent studies suggest that the PD-1/PD-1 ligand pathway contributes to the immune evasion of tumor cells in humans. 7 PD-L1 is expressed by a wide range of non-hematopoietic and hematopoietic cells including peripheral T cells. 8 The expression of PD-L2 is much more restricted than that of PD-L1, but recent studies revealed that T cells and B cells, as well as DC, express PD-L2, especially following cell activation. 9 --11 In mice, it has been shown that bone marrow-derived DC cultured with soluble PD-1 acquired a suppressive phenotype, as judged by a decreased expression of CD40, CD80 and CD86, and an increased production of IL-10, indicating reverse signaling by PD-1 ligands into DC. 12 In humans, engagement of PD-L1 on CD4 þ T cells by immobilized autoantibodies to PD-L1 in patients with rheumatoid arthritis have been shown to induce apoptosis in CD4 þ T cells. 10 Similar activity has also been observed for PD-1 ligands in Epstein-Barr virus-transformed human B cells. 13 These results prompted us to evaluate the effect of genetic modification of tumor-specific human T cells to silence their expression of PD-1 ligands as a strategy to modulate their negative regulation.
Another important attempt in genetic modification of lymphocytes for ACT is the engineering of T cells to express tumor-specific antigen receptor. This approach is suggested to overcome the difficulties associated with the preparation of T cells with high-avidity T-cell receptor (TCR) specific to tumor antigen from each patient. Pioneering work of Dembic et al.
14 demonstrated that transduction of TCR a/b genes from a well-characterized cytotoxic T-lymphocyte (CTL) clone to T cells could redirect the specificity of those T cells to the given antigen, paving the way to overcome the limitations in isolating and expanding antigenspecific T cells and to achieve broad application of this approach as a clinical treatment. Recent works indicated the feasibility and efficacy of ACT using TCR gene-engineered autologous peripheral blood T cells for cancer immunotherapy. 15 --17 We have reported the generation of CD8 þ T-cell clones that recognize a tumor-specific antigen MAGE-A4-derived peptide in a HLA-A*2402-restricted manner. 18 We isolated rearranged TCR a and b genes from one of these clones and retrovirally transdued these genes into polyclonal human lymphocytes resulting in the stable expression of the transgenes and specific cytotoxicity against MAGE-A4-expressing tumor cells. 19, 20 
In this study, we evaluated the upregulation of PD-1 ligands in MAGE-A4-specific human T-cell clones and, more importantly, in vitro propagated polyclonal CD8 þ T cells genetically modified to express MAGE-A4-specific TCR following antigen-specific activation. We challenged a question whether the small interfering RNA (siRNA) -mediated reduction of either PD-L1 or PD-L2 induces these T cells to enhance their effector functions directed against MAGE-A4 tumor antigen.
RESULTS

Human T-cell clones express PD-1 ligands on their surface
We first wished to determine whether PD-1 ligands are expressed by human CD4 þ and CD8 þ T-cell clones. When the CD8 þ T-cell clone 2 --28, specific for MAGE-A4 143À151 , and the CD4 þ T-cell clone 5, specific for MAGE-A 148À167 , were maintained in culture containing IL-2 for 2 weeks after their last antigenic stimulation, PD-L1 and PD-L2 were expressed intracellularly but not on the cell surface ( Figure 1a) . However, antigen stimulation using B-lymphoblastic cell line (LCL) pulsed with cognate peptides induced the cell surface expression of PD-L1 by these T cells (Figure 1b upper panel) . We were unable to detect PD-L2 expression by conventional staining methods, and we hypothesized that PD-L2 expression was rapidly downregulated following its interaction with PD-1 on the LCL used as antigen presenting cells, analogous to CD40 ligand expression. 21, 22 Therefore, anti-PD-L2 was added to the in vitro cultures during T-cell activation to prevent the interaction of PD-L2 with PD-1 and its subsequent downregulation. Using this approach, we were able to detect cell surface PD-L2 expression by both CD4 þ and CD8 þ T-cell clones stimulated with specific antigens (Figure 1b middle panel) . Thus chronically stimulated human T cells constitutively express PD-1 ligands intracellularly during rest, but antigen-specific activation induces cell surface expression of these proteins.
siRNA-mediated silencing of PD-1 ligands enhances T-cell function The PD-1:PD-L1/2 pathway, along with CTLA-4:B7-1/2 pathway, has been shown to have an important role in the negative regulation of T-cell function and contributes to tumor-associated T-cell tolerance. 7 To better understand the function of PD-1 ligands expressed by T cells, we wished to knockdown PD-L1 and PD-L2 expression using siRNA. Transfection of T-cell clones with siRNA oligonucleotides specific for PD-L1 and PD-L2 reduced the cell surface and mRNA expression of the target proteins (Figure 1b lower panel). The reductions of PD-1 ligands by siRNA were also confirmed by real time reverse transcriptase-PCR (Figure 1c) . Then, CD4
þ and CD8 þ T-cell clones transfected with PD-L1-or PD-L2-specific siRNA were stimulated by cognate peptide pulsed LCL that express their cognate receptors, PD-1 and B7-1 (Figure 2a ). After 24-h culture, supernatants were examined for the presence of interferon-g (IFN-g). As shown in Figure 2b , knockdown of either PD-L1 or PD-L2 expression by T-cell clones led to increased IFN-g production, and an siRNA-transfected CD8 þ T-cell clone exhibited increased lytic activity toward peptide pulsed LCL (Figure 2c) . Thus, PD-1 ligands expressed by human T-cell clones regulate T-cell effector function including cytokine production and CTL activity.
Signaling through PD-1 ligands negatively regulates T-cell function Engagement of PD-L1 initiates reverse signaling in T cells leading to the downregulation of T-cell function. 10, 23, 24 We hypothesized that the enhanced T-cell function seen in siRNA-transfected cells was at least partly due to the loss of negative regulatory signaling through PD-1 ligands. To test this possibility, CD4
þ and CD8 þ T-cell clones were stimulated in wells coated with anti-CD3 together with or without anti-PD-L1, anti-PD-L2 or both anti-PD-L1 and anti-PD-L2, and the culture supernatants were assayed for IFN-g. Cross-linking of either PD-L1 or PD-L2 led to reduced IFN-g production ( Figure 3 ), demonstrating that PD-L2 in addition to PD-L1 can deliver intrinsic signals that negatively regulate T-cell function. However, cross-linking of both PD-L1 and PD-L2 did not lead to further decrease in IFN-g production. To further confirm that the PD-1 ligands directly mediate negative regulatory signaling, we examined whether reduced IFN-g production of T-cell clones by cross-linking of PD-1 ligands was cancelled by siRNA-mediated knockdown of PD-L1 or PD-L2. As shown in Figure 3b , negative effect of cross-linking of PD-L1 or PD-L2 on IFN-g production was clearly cancelled by transduction of corresponding siRNA.
Knockdown of PD-1 ligands enhances the effector function of in vitro propagated polyclonal CD8 þ T cells transduced with a tumor antigen-specific TCR We previously established a system for generating MAGE-A4-specific CD8 þ T cells by transducing peripheral blood mononuclear cells (PBMCs) with retrovirus encoding the MAGE-4-specific TCRab derived from clone 2 --28. Using this system, we wished to determine whether polyclonal CD8 
cells was demonstrated by using MAGE-A4
þ HLA-A*2402 þ human cancer cell line 11 --18 that also express PD-1 and B7-1 ( Figure 5a ). It is noteworthy that the expression level of the only known cognate receptor for PD-L2, PD-1, is significantly low as compared with that of LCL (Figure 2a) . Accordingly, knockdown of PD-L1 but not PD-L2 enhanced lytic activity against 11 --18 to a limited extent (Figure 5b ). Taken together, our data clearly show that the negative regulatory roles of PD-L1 and PD-L2 are not confined to T-cell clones but also tumor antigen-specific TCR-transduced polyclonal CD8 þ T cells that respond physiologically to relevant doses of tumor antigen.
DISCUSSION
In the present study, we showed that human CD4 þ and CD8 þ T-cell clones, and in vitro propagated CD8 þ T cells express PD-1 ligands intracellularly and upregulate their cell surface expression rapidly after activation. siRNA-mediated knockdown of PD-1 ligands on human T cells augments the function of these cells, including IFN-g production and CTL activity, indicating that PD-1 ligands negatively regulate T-cell function. Previous studies suggested that unstimulated human CD4 þ and CD8 þ T cells did not constitutively express PD-1 ligands but induced their expression following activation. 9 --11 Recent studies in both mouse and humans suggest that PD-L1 expressed by T cells transmits intrinsic signals and regulates T-cell function. 10, 23, 24 Consistent with these data, we showed that cross-linking of PD-L1 or PD-L2 on human T-cell clones and in vitro propagated polyclonal CD8 þ T cells by immobilized mAbs suppressed IFN-g production. It is noteworthy that PD-L2 function has not been fully characterized, and we showed for the first time that PD-L2 delivers intrinsic signals that negatively regulate human T-cell function. After our initial submission of this manuscript, Messal et al. 25 recently reported that PD-L2 is expressed on activated human T cells and regulates their function, which is consistent with our results. However, all these studies, including our own, did not explore the signaling events of PD-L1 and PD-L2. Our results that cross-linking of both PD-L1 and PD-L2 on T cells did not work synergistically nor additively to suppress IFN-g production suggest that they may share the same signaling pathway to inhibit T-cell functions, despite sharing little sequence similarity between their cytoplasmic domains. The cytoplasmic domains of PD-L1 does not contain obvious structural elements that are directly relevant to signaling for cell activation or death, 10 whereas that of PD-L2 contains a putative class I PDZ motif. 26 Clearly, further studies are needed for the understanding of the intrinsic signaling pathways downstream of PD-1 ligands.
It is well established that PD-1 expressed on activated T cells negatively regulates T-cell functions upon interaction with its ligand PD-L1 and PD-L2.
5 --7 Therefore, it is possible that homotypic T-T interaction mediated by PD-1 and PD-1 ligands on T cells suppress their functions and their functional enhancement by silencing of PD-1 ligands might be due to blocking of this interaction. However, the possibility seems unlikely as siRNAmediated PD-1 knockdown of T cells did not affect their functions (data not shown). The expression level of PD-1 on T-cell populations used in our study was quite low. Therefore, it is possible that the amount of PD-1 expressed on activated T cells used in this study might be insufficient to exert negative effects on T-cell functions through direct negative signaling or indirectly through reverse signaling by PD-L1 or PD-L2. There is a discrepancy between our results and those reported by Borkner et al., 27 wherein siRNA-mediated knockdown of PD-1 in T cells is shown to enhance their functions. Likely explanations for this discrepancy involve the difference of T-cell preparations and target cells used between our and their studies, which affected the expression levels of PD-1 and PD-1 ligands. In their study, PD-1 on T cells was stably silenced by retroviral vector and PD-1 ligands on target cells were induced by IFN-g treatment, whereas those in our study employed electroporation for silencing PD-1 and used IFN-g-untreated target cells. Therefore, it is possible that the longer duration of PD-1 knockdown and the higher expression levels of ligands for PD-1 might result in this discrepancy. Activated T cells also have been reported to express another receptor for PD-L1, B7-1, 28 which we confirmed to be expressed on T-cell populations used in the present study. Therefore, it is also possible that homotypic T-T interaction mediated by B7-1 and PD-L1 is involved in the negative regulation of T-cell activation. The physiological relevance for this remains to be determined, however, the low abundance of tumor-specific T-cell in tumorbearing host may raise questions about such a possibility. Therefore, the identification of cellular populations that express the receptors for PD-1 ligands in tumor-bearing hosts is an important issue to be explored. As myeloid-derived suppressor cell-accumulating tumor sites have been shown to express high levels of PD-1 (ref. 29) and B7-1, 30 it is possible that function of CD8 þ T cells migrated into tumor site could be impaired through interaction of PD-1 ligands on T cells with PD-1 and/or B7-1 on myeloid-derived suppressor cell. Various tumors tested to date have been reported not to express PD-1. However, we found that some of human cancer cell lines, such as gastric adenocarcinoma MKN1 and MKN45, and esophageal carcinoma KE4 in addition to 11 --18, weakly expressed PD-1 and B7-1 (Figure 5a and data not shown), though it remains to be determined whether this was an artifact caused by a long-term in vitro culture. Nevertheless, we found increase in lytic activity of TCR-modified polyclonal T cells against 11 --18 to a limited extent by PD-L1. The difference in 51 Cr assay ranged about 10%, raising the need for further study to determine its physiological relevance. Recent studies suggest the existence of the receptor(s) for PD-1 ligands other than PD-1 and B7-1.
31,32 Therefore, it is also possible that PD-1 and B7-1, as well as other yet to be identified receptors for PD-1 ligands, may be expressed in some types of tumor cells that directly interact with PD-1 ligand on T cells resulting in the suppression of CTL activity against interacting tumor cells.
ACT using autologous T cells engineered to express high avidity TCR specific for a tumor antigen, which overcomes the limitations imposed by low frequency of T cells expressing high avidity TCR to tumor antigen, has been introduced as an alternative strategy with potential benefit for cancer patients. 33 However, there might still exist obstacles for ACT to be truly effective in cancer therapeutics owing to various and potent immune evasion mechanisms developed in cancer patients. 34 Such evasion mechanisms include the upregulation of coinhibitory ligands, for example, PD-1 ligands, by tumor cells and the recruitment of immunoregulatory cell, for example, myeloid-derived suppressor cells, to the tumor site. 35, 36 A recent study showed that siRNAmediated knockdown of PD-1 increases the anti-tumor activity of tumor-specific T cells. 27 These reports, together with our results here, indicate that modification of PD-1/PD-1 ligand pathway in tumor-specific T cells is an attractive approach as a future strategy for effective ACT in cancer patients.
Recently, we reported the development of novel retroviral vectors that encode both siRNA constructs that specifically downregulate endogenous TCR and a codon-optimized, therefore siRNA resistant, TCR specific for tumor antigen. 20 These vectors not only increase the expression of introduced tumor-specific TCR in transduced cells but also inhibit the generation of mispaired TCR dimers between endogenous and introduced TCR chains that can potentially create self-reactive T cells. 37 T cells transduced with these vectors enhanced the cytotoxicity against antigen-expressing tumor cells. Based on the technology utilized for the generation of these retroviral vectors, we are currently in progress to generate new retroviral vectors that encode both siRNA for PD-1 ligands and tumor antigen-specific TCRs to create þ T-cell clone 2 --28 was prepared as in a, and cytotoxicity activity against LCL pulsed with cognate peptide was measured by 51 Cr release assay. The results are expressed as mean±s.d. in triplicate. *Po0.05.
tumor-specific human T cells that are constitutively resistant to PD-1 ligands-mediated immune suppression.
We demonstrated that intrinsic signaling through both PD-L1 and PD-L2 contributes to the negative regulation of tumor-specific human T-cell functions. Our results here implicate possible enhancement of CTL function in TCR gene-modified T cells by siRNA-mediated knockdown of PD-1 ligands that may open a new approach for effective immunotherapy in cancer patients.
MATERIALS AND METHODS Cells
Human LCL were generated from several donors using Epstein-Barr virus-containing supernatants as described. 38 A human lung cancer cell line 11 --18, which express MAGE-A4 and HLA-A*2402 was obtained from American Type Culture Collection (Manassas, VA, USA). The CD8 þ T-cell clone, 2 --28, specific for the HLA-A*2402-restricted MAGE-A4 143 --151 , was generated from a normal donor as previously described. 18 The CD4 þ T-cell clone, 5, specific for HLA-DR0901-restricted MAGE -A4 148À167 , was established from normal PBMC stimulated by autologous PBMC pulsed with a MAGE-A4 overlapping peptide followed by limiting dilution as described. Polyclonal CD8 þ T cells stably expressing the TCRab genes, specific for the HLA-A*2402-restricted MAGE-A4 143 --151 , were generated by retroviral transduction of normal T cells with TCRab gene from clone 2 --28. 19 Briefly, PBMC were stimulated with 10 ng ml À1 anti-CD3 (OKT3, Jassen Pharmaceutical, Beerse, Belgium) and 40 IU ml À1 human IL-2 and transduced with the retroviral vector MS-aPb1-containing cDNA corresponding to the TCRab derived from clone 2 --28 by using the RetroNectin-bound virus infection method, wherein retroviral solutions were preloaded onto RetroNectin (Takara Bio, Otsu, Japan)-coated plates. On day 14, the cells were enriched by fluorescenceactivated cell sorting for CD8 þ MAGE-A4 143 --151 /HLA-A*2402-tetramer þ T cells on a FACSAria to a purity of 495%. These clones and cell lines were maintained by biweekly stimulation, using irradiated PBMC, irradiated LCL and anti-CD3, followed by cultivation in the presence of 40 IU ml À1 IL-2. The cells were used for experiments 2 weeks after the last stimulation. 
siRNAs transfection
Validated PD-L1 and PD-L2 siRNAs and control siRNA (stealth RNAi negative control duplex) were purchased from Invitrogen (Carlsbad, CA, USA). T cells were transfected with siRNA (10 mM) by electroporation using BTX ECM 830 square-wave electroporator (Genetronics Inc., San Diego, CA, USA) under the pre-determined condition that achieve optimal reduction of respective gene expression while retaining high viability. The transfected T cells were used for experiments after an additional 60-h culture in medium. The sequences for each siRNA were as follows: PD-L1 
Flow cytometric analysis
Unstimulated T cells or T cells stimulated with irradiated LCL pulsed with the appropriate cognate peptide for 24 h were cell surface-stained with fluorescein isothiocyanate-conjugated anti-CD4 (RPA-T4) or anti-CD8 (HIT8a) together with PE-conjugated anti-PD-L1 (M1H1) or anti-PD-L2 (M1H18) (all obtained from BD Bioscience, Mountain View, CA, USA). For some experiments, the cell surfaces were stained with fluorescein isothiocyanate-anti-CD4 or -CD8 followed by intracellular staining with PE-anti-PD-L1 or -PD-L2 using an intracellular staining kit (BD Bioscience). Additionally, for some experiments, T cells (3 Â 10 6 cells per 2 ml) were cultured with irradiated LCL (3 Â 10 6 cells per 2 ml) pulsed with cognate peptide and 7.5 ml of PE-anti-PD-L2 or control mAb for 12 h in wells of a 24-well plate containing 2 ml of culture medium. These cells were then stained with fluorescein isothiocyanate-anti-CD4 or -anti-CD8. The surface expression of PD-1 and B7.1 on LCL and other cancer cell lines were examined using anti-PD-1 mAb (MIH4) obtained from BD Bioscience and anti-B7-1 mAb (2D10.4), obtained from eBioscience. These cells were analyzed on a FACSCalibur (BD Bioscience) using CellQuest software (eBioscience, San Diego, CA, USA).
Real time reverse transcriptase-PCR
T cells transfected with siRNA specific for PD-1 ligands or control siRNA were stimulated with irradiated LCL pulsed with cognate peptide for 24 h. þ T cells prepared as described in Materials and Methods were transfected with siRNA for PD-1 ligands or control siRNA. Subsequently, their cytotoxicity activity against 11 --18 was measured by 51 Cr release assay. Non-specific cytotoxicities, as determined by using cognate peptide non-pulsed LCL were 5%, 0% and 0% at E:T ratios of 5.0, 2.5 and 1.2, respectively. The results are expressed as mean ± s.d. in triplicate. *Po0.05.
Cells were then isolated by sorting with a FACSAria (BD Bioscience) to a purity of 495% CD4 þ or CD8 þ cells. Total RNA was extracted from these cells (1 Â 10 6 cells) using an RNeasy mini kit (Qiagen, Santa Clara, CA, USA) and reverse transcribed into cDNA using avian myeloblastosis virus reverse transcriptase (Invitrogen). Quantitative real-time PCR was performed using the QuanTitect SYBR PCR Kit (Qiagen). The relative expression levels of PD-L1 and PD-L2 mRNA were normalized to the levels of GAPDH mRNA. The DDCt method was used for data analysis. Primer sequences for these reactions were as follows: PD-L1 (forward: 5 0 -TATGGTGGTGCCGACTACAA-3 0 , reverse: 3 0 -TGCTTGTCCAGATGACTTCG-5 0 ); PD-L2 (forward: 5 0 -GGGACGAAG GACAGTACCAA-3 0 , reverse: 3 0 -TTTGGCCAGGATACTTCTGC-5 0 ) and GAPDH (forward: 5 0 -GAGTCAACGGATTTGGTCGT-3 0 and reverse: 3 0 -GATCTCGCTCCT GGAAGATG-5 0 ).
Cytokine production and ELISA T-cell clones and polyclonal CD8 þ T-cell lines (1 Â 10 5 cells per 200 ml per culture) were cultured in a 96-well plate with 100 Gy-irradiated LCL (1 Â 10 4 cells per 200 ml per culture) pulsed with appropriate cognate peptide (10 mM) for 24 h. In some experiments, T cells were cultured with irradiated LCL pulsed with appropriate cognate peptide for 24 h, purified by positive selection using anti-CD4 or anti-CD8 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany), replated at 1 Â 10 5 cells 200 ml À1 per culture in a 96-well flat plate previously coated with 50 ng ml À1 of anti-CD3 together with 30 mg ml À1 control IgG, 15 mg ml À1 anti-PD-L1 (MIH1) plus 15 mg ml À1 control IgG, 15 mg ml À1 anti-PD-L2 (MIH18) plus 15 mg ml
À1
control IgG or 15 mg ml À1 of each anti-PD-L1 and PD-L2 and cultured for an additional 24 h. The concentrations of IFN-g in the supernatants were measured by using a human IFN-g ELISA kit (Mabtech, Nacka, Sweden).
Cytotoxic T-lymphocyte assay 51
Cr-release cytotoxicity assay was conducted as described previously. 39 
Statistics
All data were subjected to Shapiro --Wilk normality test and confirmed for the normal distribution. Accordingly, Student's t-test and ANOVA with Scheffe's test for comparison between two groups and groups of more than three, respectively, were employed for statistical analysis. A P-value of o0.05 was considered significant. All experiments were performed at least twice.
